The Efficacy and Safety of Low Dose Combination of LTG and VPA Compared to CBZ Monotherapy

NCT ID: NCT00807989

Last Updated: 2015-07-27

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

207 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-03-31

Study Completion Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the efficacy of usual monotherapy and low dose combination of Lamotrigine and Valproate. Low dose combination may be more effective and tolerable because they are low dose and VPA reduce Lamotrigine metabolism.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

An Open label, Randomized, Multicenter Clinical Trial to Compare the Efficacy and Safety of Lamotrigine / Valproate Coadministration and Carbamazepine as Initial Pharmacotherapy in Epilepsies

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epilepsy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Carbamazepine

Carbamazepine

Group Type ACTIVE_COMPARATOR

Carbamazepine

Intervention Type DRUG

Lamotrigine/Valproate

Lamotrigine and Valproate combination therapy

Group Type EXPERIMENTAL

Lamotrigine/Valproate

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Carbamazepine

Intervention Type DRUG

Lamotrigine/Valproate

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥16yr old
* Who are diagnosed as epilepsy definitely
* Who have minimum 2 unprovoked seizures and minimum 1 seizure in previous 3 months
* Who need AED therapy and no AED medication for previous 1 year (exclude emergency medication for less than 2weeks)
* Who is not pregnant
* Who can report seizure diary by him/herself or caregiver
* Who agree to this trial and provide informed consent.
* Type of seizures : of generalized tonic-clonic, complex partial, and/or simple partial motor seizures;

Exclusion Criteria

* Who has progressive CNS disease.
* Has serious systemic or psychiatric disease
* Who is not suitable by investigator(uncooperative)
* Who can not fill up diary check card
* Is pregnant, breastfeeding, or planning to become pregnant
* Exclusion - absence s. juvenile myoclonic epilepsy, atonic seizure, alcohol or other substance abusers, mental retardation etc.
* Who cancels to agree to this trial and provide informed consent.
* ALT, AST, bilirubin and BUN/Cr levels are more than twice normal range of them
* WBC value is 2000 and less, Hb value is 9.0 and less, platelet count is 100,000 and less in CBC
* Who took investigation products before participating this study
Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Yonsei University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Byung-In Lee

Role: PRINCIPAL_INVESTIGATOR

Yonsei Univ.

Kyoung Heo

Role: PRINCIPAL_INVESTIGATOR

Yonsei Univ.

Sang-Kun Lee

Role: PRINCIPAL_INVESTIGATOR

Seoul National Univ.

Sang-Ahm Lee

Role: PRINCIPAL_INVESTIGATOR

Ulsan Univ.

Dong-Jin Shin

Role: PRINCIPAL_INVESTIGATOR

Gacheon Univ.

Hong-Ki Song

Role: PRINCIPAL_INVESTIGATOR

Hallym Univ.

Young-In Kim

Role: PRINCIPAL_INVESTIGATOR

Catholic Univ.

Se-Jin Lee

Role: PRINCIPAL_INVESTIGATOR

Youngnam Univ.

Sang-Ho Kim

Role: PRINCIPAL_INVESTIGATOR

Donga Univ.

Myung-Gyu Kim

Role: PRINCIPAL_INVESTIGATOR

Cheonnam Univ.

Yo-Sik Kim

Role: PRINCIPAL_INVESTIGATOR

Wonkwang Univ.

Sang-Do Lee

Role: PRINCIPAL_INVESTIGATOR

Dongsan Hosp.

Sung-Eun Kim

Role: PRINCIPAL_INVESTIGATOR

Pusan-Bak Hosp.

Sung-Pa Park

Role: PRINCIPAL_INVESTIGATOR

Kyungbuk Univ.

Joo-Yong Kim

Role: PRINCIPAL_INVESTIGATOR

Hanrim Univ.

Ok-Jun Kim

Role: PRINCIPAL_INVESTIGATOR

Bundang Cha

Soon-Ki Noh

Role: PRINCIPAL_INVESTIGATOR

Bong-Sang Hosp.

Hyang-Woon Lee

Role: PRINCIPAL_INVESTIGATOR

I-wha Univ.

Jae-Moon Kim

Role: PRINCIPAL_INVESTIGATOR

Chungnam Univ.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Yonsei Medical Center

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

109887

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.